Evidence map›Paper›PMID 38476274›Full record

ArticleInternational journal of nanomedicine2024

Blood-Nanoparticle Interactions Create a Brain Delivery Superhighway for Doxorubicin.

Zhuoxuan Li, Tatyana Kovshova, Julia Malinovskaya, Julian Knoll, Saeed Shanehsazzadeh, Nadezhda Osipova, Anastasia Chernysheva, Pavel Melnikov, Svetlana Gelperina, Matthias G Wacker

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of nanomedicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Zhuoxuan LiNational University of Singapore, Department of Pharmacy and Pharmaceutical Sciences, Faculty of Science, Singapore.
Tatyana KovshovaDmitry Mendeleev University of Chemical Technology of Russia, Moscow, Russia.
Julia MalinovskayaDmitry Mendeleev University of Chemical Technology of Russia, Moscow, Russia.
Julian KnollNational University of Singapore, Department of Pharmacy and Pharmaceutical Sciences, Faculty of Science, Singapore.
Saeed ShanehsazzadehNational University of Singapore, Department of Pharmacy and Pharmaceutical Sciences, Faculty of Science, Singapore.
Nadezhda OsipovaDmitry Mendeleev University of Chemical Technology of Russia, Moscow, Russia.
Anastasia ChernyshevaV. Serbsky Federal Medical Research Centre of Psychiatry and Narcology of the Ministry of Health of the Russian Federation, Moscow, Russia.
Pavel MelnikovDmitry Mendeleev University of Chemical Technology of Russia, Moscow, Russia.
Svetlana GelperinaDmitry Mendeleev University of Chemical Technology of Russia, Moscow, Russia.ORCID 0000-0003-1113-6715
Matthias G WackerNational University of Singapore, Department of Pharmacy and Pharmaceutical Sciences, Faculty of Science, Singapore.ORCID 0000-0002-2789-6463
D. Mendeleyev University of Chemical Technology of Russia · RUNational University of Singapore · SGMinistry of Health of the Russian Federation · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: This study investigated the brain targeting mechanism of doxorubicin-loaded polybutyl cyanoacrylate (PBCA) nanoparticles, particularly their interactions with the blood-brain barrier (BBB). The BBB protects the brain from drugs in the bloodstream and represents a crucial obstacle in the treatment of brain cancer. Methods: An advanced computer model analyzed the brain delivery of two distinct formulations, Doxil Results: Our analysis yielded a surprising discovery regarding the brain delivery mechanism of PBCA nanoparticles. While Doxil Conclusion: The nonspecific binding to blood cells facilitated and intensified interactions of surfactant-coated PBCA nanoparticles with the vascular endothelium, leading to enhanced transcytosis. Consequently, the significant increase in circulation time in the bloodstream, coupled with improved receptor interactions, contributes to this remarkable uptake of doxorubicin into the brain.

Indexed as

EnbucrilateNanoparticlesBlood-Brain BarrierBrainDoxorubicinDrug CarriersPolyethylene GlycolsSurface-Active AgentsDoxorubicinDrug CarriersEnbucrilateliposomal doxorubicinPolyethylene GlycolsSurface-Active AgentsBBBbrain targetingCNSdoxorubicindrug deliverymodeling

Identifiers

PMID38476274
PMCPMC10928925
OpenAlexW4392375357

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.